中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 2
Feb.  2018
Turn off MathJax
Article Contents

Pathological features of liver tissue in autoantibody-positive chronic hepatitis C patients after plasmaphoresis

DOI: 10.3969/j.issn.1001-5256.2018.02.013
Research funding:

 

  • Published Date: 2018-02-20
  • Objective To investigate the detection rate and features of autoantibodies in chronic hepatitis C (CHC) patients after plasmaphoresis, as well as the liver pathological features of autoantibody-positive CHC patients.Methods A total of 120 patients who were infected with hepatitis C virus after plasmaphoresis in the Hospital of Dingxi County and Dingxi Hospital of Infectious Diseases from January1992 to December 1995 were selected as test group; 11 healthy people from the same region were selected as control group.Autoantibody detection was performed for the 120 CHC patients, and liver pathological features were compared between the autoantibody-positive group (n = 44) and autoantibody-negative group (n = 76) of these patients.The t test was used for comparison of continuous data, and the chi-square test was used for comparison of categorical data.Results Of all 120 CHC patients who underwent plasmaphoresis, 44 (36.7%) were found to have serum autoantibodies, with antinuclear antibodies as the most common type (21.7%) .Compared with the autoantibody-negative group, the autoantibody-positive group had significantly higher scores of focal necrosis inside the hepatic lobules (2.11 ± 0.88 vs 1.64 ±0.88, t = 2.349, P = 0.021) and ductular reaction inside the portal area (1.86 ± 0.71 vs 1.13 ± 0.66, t = 4.217, P < 0.001) , as well as a significantly higher rate of interlobular bile duct injury (86.4% vs 55.3%, χ2= 12.129, P = 0.001) .There were no significant differences between the two groups in the degree of liver fibrosis and hepatic steatosis (both P > 0.05) .Conclusion Autoantibody-positive are common in CHC patients after plasmaphoresis, and autoantibody-positive patients tend to have more severe injuries of the liver.

     

  • loading
  • [1]LAVANCHY D.The global burden of hepatitis C[J].Liver Int, 2009, 29 (Suppl 1) :74-81.
    [2]MOHD HANAFIAH K, GROEGER J, FLAXMAN AD, et al.Global epidemiology of hepatitis C virus infection:new estimates of age-specific antibody to HCV seroprevalence[J].Hepatology, 2013, 57 (4) :1333-1342.
    [3]GOMEZ EV, RODRIGUEZ YS, BERTOT LC, et al.The natural history of compensated HCV-related cirrhosis:a prospective long-term study[J].J Hepatol, 2013, 58 (3) :434-444.
    [4]DASCHAKRABORTY S, AGGARWAL A, AGGARWAL R.Non-organ-specific autoantibodies in indian patients with chronic liver disease[J].Indian J Gastroenterol, 2012, 31 (5) :237-242.
    [5]MARCONCINI ML, FAYAD L, SHIOZAWA MB, et al.Autoantibody profile in individuals with chronic hepatitis C[J].Rev Soc Bras Med Trop, 2013, 46 (2) :147-153.
    [6]SANSONNO L, TUCCI FA, SANSONNO S, et al.B cells and HCV:an infection model of autoimmunity[J].Autoimmun Rev, 2009, 9 (2) :93-94.
    [7]BAYRAKTAR Y, BAYRAKTAR M, GURAKAR A, et al.A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis:the role of interferon in the development of autoimmune diseases[J].Hepatogastroenterology, 1997, 44 (14) :417-425.
    [8]YEE LJ, KELLENHER P, GOLDIN RD, et al.Antinuclear antibodies (ANA) in chronic hepatitis C virus infection:correlates of positivity and clinical relevance[J].J Viral Hepat, 2004, 11 (5) :459-464.
    [9]PENG YC, HAIEH SC, YANG DY, et al.Expression and clinical significance of antinuclear antibody in hepatitis C virus infection[J].J Clin Gastroenterol, 2001, 33 (5) :402-406.
    [10]CASSANI F, CATALETA M, VALENTINI P, et al.Serum autoantibodies in chronic hepatitis C:comparison with autoimmune hepatitis and impact on the disease profile[J].Hepatology, 1997, 26 (3) :561-566.
    [11]RIGOPOULOU EI, MYTILINAIOU M, ROMANIDOU O, et al.Autoimmune hepatitis-specific antibodies against soluble liver antigen and liver cytosol type 1 in patients with chronic viral hepatitis[J].J Autoimmune Dis, 2007, 4:2.
    [12]NARCISO-SCHIAVON JL, SCHIAVON LDE L.Autoantibodies in chronic hepatitis C:a clinical perspective[J].World J Hepatol, 2015, 7 (8) :1074-1085.
    [13]STROFFOLINI T, COLLOREDO G, GAETA GB, et al.Does an‘autoimmune’profile affect the clinical profile of chronic hepatitis C?An italian multicentre survey[J].J Viral Hepat, 2004, 11 (3) :257-262.
    [14]Chinese Society of Hepatology and Chinese Society of Infectious Diseases Chinese, Medical Association.The guideline of prevention and treatment for hepatitis C:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.
    [15]ISHAK K, BAPTISTA A, BIANCHI L, et al.Histological grading and staging of chronic hepatitis[J].J Hepatol, 1995, 22 (6) :696-699.
    [16]BRUNT EM.Pathology of fatty liver disease[J].Mod Pathol, 2007, 20 (Suppl 1) :s40-s48.
    [17]VERGANI D, ALVAREZ F, BIANCHI FB, et al.Liver autoimmune serology:a consensus statement from the committee for autoimmune serology of the international autoimmune hepatitis group[J].J Hepatol, 2004, 41 (4) :677-683.
    [18]KUNIHOLM MH, GAO X, XUE X, et al.The relation of HLA genotype to hepatitis C viral load and markers of liver fibrosis in HIV-infected and HIV-uninfected women[J].J Infect Dis, 2011, 203 (12) :1807-1814.
    [19]KERKAR N, CHOUHURI K, MA Y, et al.Cytochrome p4502d6 (193-212) :a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease[J].J Immunol, 2003, 170 (3) :1481-1489.
    [20]SUTTI S, VIDALI M, MOMBELLO C, et al.Conformational anticytochrome P4502E1 (CYP2E1) auto-antibodies contribute to necro-inflammatory injury in chronic hepatitis C[J].J Viral Hepat, 2010, 17 (10) :685-690.
    [21]MIZUOCHI T, ITO M, TAKAI K, et al.Differential susceptibility of peripheral blood CD5+and CD5-B cells to apoptosis in chronic hepatitis C patients[J].Biochem Biophys Res Commun, 2009, 389 (3) :512-515.
    [22]CLAASSEN MA, DE KNEGT RJ, TILANUS HW, et al.Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis[J].J Hepatol, 2010, 52 (3) :315-321.
    [23]WILLIAMS MJ, LAWSON A, NEAL KR, et al.Autoantibodies in chronic hepatitis C virus infection and their association with disease profile[J].J Viral Hepat, 2009, 16 (5) :325-331.
    [24]LI WS, ZHAO JM, ZHOU GD, et al.The impact of autoantibodies on liver histology in hepatitis C[J/CD].Chin J Clinicians:Electronic Edition, 2011, 5 (20) :5969-5973. (in Chinese) 李文淑, 赵景民, 周光德, 等.HCV感染者自身抗体对肝脏损伤的影响[J/CD].中华临床医师杂志:电子版, 2011, 5 (20) :5969-5973.
    [25]ROSKAMS TA, THEISE ND, BALABAUD C, et al.Nomenclature of the finer branches of the biliary tree:canals, ductules, and ductular reactions in human livers[J].Hepatology, 2004, 39 (6) :1739-1745.
    [26]GOUW AS, CLOUSTON AD, THEISE ND.Ductular reactions in human liver:diversity at the interface[J].Hepatology, 2011, 54 (5) :1853-1863.
    [27]AZMAIPARASHVILI E, BERISHVILI E, KAKABADZE Z, et al.Ductular reaction at the early terms of common bile duct ligation in the rats[J].Acta Biol Hung, 2012, 63 (3) :321-332.
    [28]AFSARI A, LEE E, SHOKRANI B, et al.Clinical and pathological risk factors associated with liver fibrosis and steatosis in african-americans with chronic hepatitis C[J].Dig Dis Sci, 2017, 62 (8) :2159-2165.
    [29]KAROUI S, TAIEB JOMI M, BELLIL K, et al.Steatosis in chronic viral hepatitis C:frequency, risk factors and relationship with fibrosis[J].Tunis Med, 2008, 86 (7) :670-675.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (2193) PDF downloads(432) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return